Search by Drug Name or NDC

    NDC 00363-0541-36 Walgreens Antacid Pain Relief Extra Strength 1000; 500; 1985 mg/1; mg/1; mg/1 Details

    Walgreens Antacid Pain Relief Extra Strength 1000; 500; 1985 mg/1; mg/1; mg/1

    Walgreens Antacid Pain Relief Extra Strength is a ORAL TABLET, EFFERVESCENT in the HUMAN OTC DRUG category. It is labeled and distributed by Walgreens. The primary component is ANHYDROUS CITRIC ACID; ASPIRIN; SODIUM BICARBONATE.

    Product Information

    NDC 00363-0541
    Product ID 0363-0541_e054113d-bc9c-4763-e053-2995a90a3e4c
    Associated GPIs
    GCN Sequence Number n/a
    GCN Sequence Number Description n/a
    HIC3 n/a
    HIC3 Description n/a
    GCN n/a
    HICL Sequence Number n/a
    HICL Sequence Number Description n/a
    Brand/Generic n/a
    Proprietary Name Walgreens Antacid Pain Relief Extra Strength
    Proprietary Name Suffix n/a
    Non-Proprietary Name Aspirin, Citric Acid, Sodium Bicarbonate
    Product Type HUMAN OTC DRUG
    Dosage Form TABLET, EFFERVESCENT
    Route ORAL
    Active Ingredient Strength 1000; 500; 1985
    Active Ingredient Units mg/1; mg/1; mg/1
    Substance Name ANHYDROUS CITRIC ACID; ASPIRIN; SODIUM BICARBONATE
    Labeler Name Walgreens
    Pharmaceutical Class Acidifying Activity [MoA], Alkalinizing Activity [MoA], Anti-Inflammatory Agents, Non-Steroidal [CS], Anti-coagulant [EPC], Calcium Chelating Activity [MoA], Calculi Dissolution Agent [EPC], Cyclooxygenase Inhibitors [MoA], Decreased Coagulation Factor Ac
    DEA Schedule n/a
    Marketing Category OTC MONOGRAPH FINAL
    Application Number part343
    Listing Certified Through 2024-12-31

    Package

    NDC 00363-0541-36 (00363054136)

    NDC Package Code 0363-0541-36
    Billing NDC 00363054136
    Package 18 POUCH in 1 CARTON (0363-0541-36) / 2 TABLET, EFFERVESCENT in 1 POUCH
    Marketing Start Date 2021-02-05
    NDC Exclude Flag N
    Pricing Information N/A

    Standard Product Labeling (SPL)/Prescribing Information SPL b60df498-07db-500b-e053-2a95a90aff6a Details

    Revised: 5/2022